Clinical prolife and outcome in COVID-19 patients on treatment regimen of remdesivir, favipiravir, and non-antiviral drugs

Background: Although various drugs have been used in the treatment of COVID-19 infections, specific drug with good therapeutic outcome is still unclear. They are using remdesivir, favipiravir, ivermectin, azithromycin, and so on. Aim and Objectives: This study aimed to evaluate the clinical profile...

Full description

Saved in:
Bibliographic Details
Published in:National journal of physiology, pharmacy and pharmacology pharmacy and pharmacology, 2023, Vol.13 (7), p.1-1477
Main Authors: Shetti, Santoshkumar, G, Manu, Walwekar, Rekha
Format: Article
Language:English
Subjects:
Antiviral drugs
Asymptomatic
Comorbidity
Complaints
COVID-19
Diabetes
Disease transmission
Drug therapy
Fever
Headaches
Hypertension
Influenza
Medical records
Medical schools
Morbidity
Mortality
Pandemics
Patients
Pneumonia
RNA polymerase
Severe acute respiratory syndrome coronavirus 2
Teaching hospitals
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Although various drugs have been used in the treatment of COVID-19 infections, specific drug with good therapeutic outcome is still unclear. They are using remdesivir, favipiravir, ivermectin, azithromycin, and so on. Aim and Objectives: This study aimed to evaluate the clinical profile of patients treated with different regimens and their outcome in improvement or morbidity of patients. Materials and Methods: We conducted a cross-sectional questionnaire-based study after approval by the institutional ethics committee. Data were collected from case files of COVID-19-positive patients treated in COVID-19 ward in Bharati Hospital, Sangli. We collected as per our protocol pro forma as – routine COVID treatment with remdesivir, favipiravir, and non-antiviral drugs. We analyzed various clinical profiles (presenting complaints), duration of stay in COVID wards, their outcome as improved and discharged, or deaths occurred. Results: It was observed that majority 54% of patients were from 40 to 50 years’ range. There was male preponderance 64%. Clinical symptoms were fever (92%), cough (85%), sore throat (77%), headache (53%), and breathlessness (10%). Majority of them were diabetes mellitus (51%), obesity (22%), and hypertension. Ventilatory support needed in 18%, rest recovered on pharmacotherapy. Conclusion: One of the highly infectious diseases causing COVID-19 is contagious and transmitted through airborne droplets generated by sneezing, smooching, and coughing. So as per the WHO and CDC guidelines avoid close contact with these infected persons in a market or public place. Vaccines available against COVID-19 Covishield and Covaxin to prevent the severity and to have immunity against COVID should be taken by all.
ISSN:2320-4672
2231-3206
DOI:10.5455/njppp.2023.13.05254202319052023